Research
Hormonal
The STEP HFpEF and SELECT trials demonstrated that semaglutide improves clinical outcomes in obese HFpEF patients and reduces cardiovascular and heart failure events in non-diabetic obese patients.
Practitioners should consider semaglutide as a treatment option for improving outcomes in obese HFpEF patients.
StrongSupportsmedium confidence
The STEP HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) and SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trials recently demonstrated that the glucagon-like peptide 1 analogue, semaglutide, improves various aspects of clinical outcomes in obese HFpEF patients and significantly reduces cardiovascular and heart failure events in non-diabetic obese patients.
Why this rating
Based on the mention of large trials (STEP HFpEF and SELECT).
Source
Targeting obesity for therapeutic intervention in heart failure patients
Ryosuke Sato et al. · Expert Review of Cardiovascular Therapy · 2024
reviewCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →